Review of new guidelines for the management of glucocorticoid induced osteoporosis

Current Osteoporosis Reports

Volumn 11, Issue 4, 2013, Pages 357-364

  Venuturupalli, Swamy R ^a   Sacks, Wendy ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Future treatments; Glucocorticoids; Guidelines; Osteoporosis; Therapeutics

Indexed keywords

ALENDRONIC ACID; ALFACALCIDOL; CALCITRIOL; CALCIUM; CATHEPSIN K INHIBITOR; DENOSUMAB; ETIDRONIC ACID; GLUCOCORTICOID; ODANACATIB; ONO 454; PARATHYROID HORMONE[1-34]; RISEDRONIC ACID; ROMOSOZUMAB; UNCLASSIFIED DRUG; VITAMIN D; ZOLEDRONIC ACID;

ALGORITHM; ARTICLE; CLINICAL ASSESSMENT; CORTICOSTEROID INDUCED OSTEOPOROSIS; HUMAN; PATIENT COUNSELING; PATIENT MONITORING; PRACTICE GUIDELINE; PUBLICATION; TREATMENT INDICATION; UNITED STATES;

ALGORITHMS; CALCIUM; DIPHOSPHONATES; GLUCOCORTICOIDS; HUMANS; OSTEOPOROSIS; PRACTICE GUIDELINES AS TOPIC; RHEUMATIC DISEASES; VITAMIN D;

EID: 84890080011     PISSN: 15441873     EISSN: 15442241     Source Type: Journal    
DOI: 10.1007/s11914-013-0170-3     Document Type: Article

References (57)

1. Diez-Perez A et al. Regional differences in treatment for osteoporosis. The Global Longitudinal Study of Osteoporosis in Women (GLOW). Bone. 2011;9(3):493-8.
2. van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int. 2002;13(10):777-87.
3. Recommendations for the prevention and treatment of glucocorticoid- induced osteoporosis: 2001 update. Arthritis Rheum. 2001;44(7):1496-503.
4. Bone and Tooth Society of Great Britain. Guidelines on the prevention and treatment of glucocorticoid-induced osteoporosis. London: Royal College of Physicians; 2003.
5. Devogelaer JP et al. Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club. Osteoporos Int. 2006;17(1):8-19.
6. • Grossman JM et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res. 2010;62(11):1515-26. These guidelines provide a risk stratification strategy for the assessment of those patients with GIO who need treatment.
7. • Lekamwasam S et al. A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int. 2012;23(9):2257-76. These guidelines provide additional information about risk stratification especially for countries in which bone density testing is not freely available. Additionally, strength of evidence for various interventions is discussed.
8. • Pereira RM et al. Guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis. Rev Bras Reumatol. 2012;52(4):580-93. These are updated guidelines that provide detailed analysis of the strength of the evidence for various recommendations for the assessment and management of GIO.
9. • Leib ES et al. Official positions for FRAX((R)) clinical regarding glucocorticoids: the impact of the use of glucocorticoids on the estimate by FRAX((R)) of the 10 year risk of fracture from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX((R)). J Clin Densitom. 2011;14(3):212-9. This article provides the rationale to adjust FRAX based on corticosteroid dose.
10. • Kanis JA et al. Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int. 2011;22(3):809-16. This article provides guidelines for adjustment of FRAX according to GC dose.
11. Kanis JA et al. Interpretation and use of FRAX in clinical practice. Osteoporos Int. 2011;22(9):2395-411.
12. Kanis JA et al. Case finding for the management of osteoporosis with FRAX-assessment and intervention thresholds for the UK. Osteoporos Int. 2008;19(10):1395-408.
13. Compston J et al. Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas. 2009;62(2):105-8.
14. Morris HA et al. Malabsorption of calcium in corticosteroid-induced osteoporosis. Calcif Tissue Int. 1990;46(5):305-8.
15. Sambrook P et al. Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin. N Engl J Med. 1993;328(24):1747-52.
16. Yeap SS et al. A comparison of calcium, calcitriol, and alendronate in corticosteroid-treated premenopausal patients with systemic lupus erythematosus. J Rheumatol. 2008;35(12):2344-7.
17. Richy F et al. Efficacy of alphacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate. Osteoporos Int. 2004;15(4):301-10.
18. Sambrook P et al. Effect of calcitriol on bone loss after cardiac or lung transplantation. J Bone Miner Res. 2000;15(9):1818-24.
19. Amin S et al. The role of vitamin D in corticosteroid-induced osteoporosis: a meta-analytic approach. Arthritis Rheum. 1999;42(8):1740-51.
20. Homik J et al. Calcium and vitamin D for corticosteroid-induced osteoporosis. Cochrane Database Syst Rev. 2000;2, CD000952.
21. Richy F et al. Vitamin D analogs vs native vitamin D in preventing bone loss and osteoporosis-related fractures: a comparative meta-analysis. Calcif Tissue Int. 2005;76(3):176-86.
22. Sambrook PN et al. Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium. J Bone Miner Res. 2003;18(5):919-24.
23. Saag KG et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med. 1998;339(5):292-9.
24. de Nijs RN et al. Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. N Engl J Med. 2006;355(7):675-84.
25. Adachi JD et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum. 2001;44(1):202-11.
26. Reid DM et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res. 2000;15(6):1006-13.
27. Cohen S et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 1999;42(11):2309-18.
28. Reid DM et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicenter, double-blind, double-dummy, randomized controlled trial. Lancet. 2009;373(9671):1253-63.
29. Ringe JD et al. Three-monthly ibandronate bolus injection offers favourable tolerability and sustained efficacy advantage over two years in established corticosteroid-induced osteoporosis. Rheumatology (Oxford). 2003;42(6):743-9.
30. Ringe JD et al. Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study. Osteoporos Int. 2003;14(10):801-7.
31. Hakala M et al. Once-monthly oral ibandronate provides significant improvement in bone mineral density in postmenopausal women treated with glucocorticoids for inflammatory rheumatic diseases: a 12-month, randomized, double-blind, placebo-controlled trial. Scand J Rheumatol. 2012;41(4):260-6.
32. Plotkin LI et al. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest. 1999;104(10):1363-74.
33. Weinstein RS et al. Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids. J Clin Invest. 2002;109(8):1041-8.
34. Weinstein RS, Roberson PK, Manolagas SC. Giant osteoclast formation and long-term oral bisphosphonate therapy. N Engl J Med. 2009;360(1):53-62.
35. Jadu F et al. A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients. Ann Oncol. 2007;18(12):2015-9.
36. Langdahl BL et al. Teriparatide vs alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status. Osteoporos Int. 2009;20(12):2095-104.
37. Saag KG et al. Effects of teriparatide vs alendronate for treating glucocorticoid-induced osteoporosis: 36-month results of a randomized, double-blind, controlled trial. Arthritis Rheum. 2009;60(11):3346-55.
38. Devogelaer JP et al. Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis. J Rheumatol. 2010;37(1):141-8.
39. Gluer CC, et al. Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial. J Bone Miner Res. 2013.
40. MacAdams MR, White RH, Chipps BE. Reduction of serum testosterone levels during chronic glucocorticoid therapy. Ann Intern Med. 1986;104(5):648-51.
41. Laatikainen AK et al. Bone mineral density in perimenopausal women with asthma: a population-based cross-sectional study. Am J Respir Crit Care Med. 1999;159(4 Pt 1):1179-85.
42. Reid IR et al. Testosterone therapy in glucocorticoid-treated men. Arch Intern Med. 1996;156(11):1173-7.
43. Cranney A, et al. Calcitonin for the treatment and prevention of corticosteroid-induced osteoporosis. Cochrane Database Syst Rev, 20;2:CD001983.
44. • Rizzoli R et al. Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report. Osteoporos Int. 2011;22(2):373-90. This study summarizes the research on the occurrence of sub-trochanteric femur fractures and their association with bisphosphonates.
45. • Park-Wyllie Ly MMMJDN et al. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA. 2011;305(8):783-9. Another important study that links bisphosphonates to the occurrence of sub-trochanteric fractures.
46. Wang Z, Bhattacharyya T. Trends in incidence of subtrochanteric fragility fractures and bisphosphonate use among the US elderly, 1996-2007. J Bone Min Res. 2011;26(3):553-60.
47. Giusti A et al. Atypical fractures and bisphosphonate therapy: a cohort study of patients with femoral fracture with radiographic adjudication of fracture site and features. Bone. 2011;48(5):966-71.
48. Cummings SR et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756-65.
49. Hofbauer LC et al. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology. 1999;140(10):4382-9.
50. Sivagurunathan S et al. Influence of glucocorticoids on human osteoclast generation and activity. J Bone Miner Res. 2005;20(3):390-8.
51. Dore RK et al. Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates. Ann Rheum Dis. 2010;69(5):872-5.
52. Boonen S et al. Inhibition of cathepsin K for treatment of osteoporosis. Curr Osteoporos Rep. 2012;10(1):73-9.
53. Brixen K, et al. Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: a randomized trial. J Clin Endocrinol Metab. 2013;98:571-80.
54. Nagase S et al. Serum and urine bone resorption markers and pharmacokinetics of the cathepsin K inhibitor ONO-5334 after ascending single doses in postmenopausal women. Br J Clin Pharmacol. 2012;74(6):959-70.
55. Hayashi K et al. BMP/Wnt antagonists are upregulated by dexamethasone in osteoblasts and reversed by alendronate and PTH: potential therapeutic targets for glucocorticoid-induced osteoporosis. Biochem Biophys Res Commun. 2009;379(2):261-6.
56. Yao W et al. Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis: a longitudinal study of gene expression in bone tissue from glucocorticoid- treated mice. Arthritis Rheum. 2008;58(6):1674-86.
57. Kanis JA et al. Case finding for the management of osteoporosis with FRAX - assessment and intervention thresholds for the UK. Osteoporos Int. 2009;19:1395-408 Erratum. Osteoporos Int. 2008;20:499-502.